Hepatitis C viremia as a risk factor for opportunistic infections in kidney transplant recipients.

Direct-acting antivirals are effective and safe in HCV/HIV-coinfected liver transplant recipients who experience recurrence of hepatitis C: A prospective nationwide cohort study.

Molecular profiling of subclinical inflammatory lesions in long-term surviving adult liver transplant recipients.

Long-Term Outcomes of Patients With HCV-Associated Cryoglobulinemic Vasculitis After Virologic Cure.

Insulin receptor substrate-4 is overexpressed in colorectal cancer and promotes retinoblastoma-cyclin-dependent kinase activation.

The efficacy of direct anti-HCV drugs improves early post-liver transplant survival and induces significant changes in waiting list composition.

Can bioprosthetic valve thrombosis be promoted by aortic root morphology? An in vitro study.

Potential drug-drug interactions of OMBITASVIR, PARITAPREVIR/ritonavir Âą DASABUVIR Âą ribavirin in clinical practice.

Anti-viral therapy can be delayed or avoided in a significant proportion of HBeAg-negative Caucasian patients in the Grey Zone.

Viral eradication and fibrosis resolution in post-liver transplant cholestatic hepatitis C virus.

Portal pressure and liver stiffness measurements in the prediction of fibrosis regression after sustained virological response in recurrent hepatitis C.

Reply to: "Extended DAA indications for hepatitis C patients awaiting liver transplantation and further statistical considerations".

Recommendations for the treatment of hepatitis C virus infection in chronic kidney disease: a position statement by the Spanish association of the liver and the kidney.

Casualties of peace: an analysis of casualties admitted to the intensive care unit during the negotiation of the comprehensive Colombian process of peace.

Clinical outcomes of patients undergoing antiviral therapy while awaiting liver transplantation.